资讯

Cardiovascular disease (CVD) mortality increased by 78%, rising from 72.4 to 128.7 per 100 000 (2017–2022), with the greatest ...
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight ...
Mariann R. Piano, Gregory M. Marcus, Dawn M. Aycock, Jennifer Buckman, Chueh-Lung Hwang, Susanna C. Larsson, Kenneth J. Mukamal, Michael Roerecke, [...] on behalf the American Heart Association ...
Evidence of myocardial injury does not necessitate a diagnosis of myocarditis. When a cardiac troponin level is over the 99th percentile of the upper reference limit, 6 there exists a spectrum of ...
Identification of children with latent rheumatic heart disease (RHD) by echocardiography, before onset of symptoms, provides an opportunity to initiate secondary prophylaxis and prevent disease ...
Versican, a cardiac fibroblast–derived extracellular matrix component, was upregulated after neonatal myocardial injury and promoted cardiomyocyte proliferation. Conditional knockout of Vcan in ...
BACKGROUND: Evaluation of whether dyspnea has a cardiac cause is essential. Guidelines from 2016 were reported to result in a ...
We performed a systematic review of MEDLINE and Embase for randomized trials comparing oral anticoagulation with antiplatelet or no antithrombotic therapy in adults with device-detected atrial ...
In the combined cohort, the median NFL level was 16.9 ng/L (interquartile range, 11.1–26.5 ng/L), the median age was 71 years, 58% were men, and 13% had a history of previous stroke. NFL was ...
Occlusions of medium-sized intracranial arteries (MeVOs) account for 25% to 40% of all acute ischemic strokes. 1 Some authors have defined MeVOs as occlusions of the M2/3, A2/3, or P2/3 segments ...
Gene Ontology analysis from differentially expressed genes revealed expected changes in cell cycle, metabolism, and contractility. In addition, mRNA splicing was among the top enriched differentially ...
BACKGROUND: In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, ...